Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment (Q44624341)

4 December 2017

title

Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment (English)

1 reference

4 December 2017

Roger Roulier

1

1 reference

4 December 2017

Véronique Chabert-Orsini

2

1 reference

4 December 2017

Marie-Christine Sitri

3

1 reference

4 December 2017

Bernard Barry

4

1 reference

4 December 2017

P. Terriou

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14567887

23 March 2024

language of work or name

1 reference

1 September 2003

1 reference

full work available at URL

4 December 2017

https://api.elsevier.com/content/article/PII:S147264831061749X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1472-6483(10)61749-X

https://api.elsevier.com/content/article/PII:S147264831061749X?httpAccept=text/plain

23 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1472-6483(10)61749-X

Reproductive BioMedicine Online

23 March 2024

published in

1 reference

4 December 2017

volume

7

1 reference

4 December 2017

issue

2

1 reference

4 December 2017

page(s)

185-189

1 reference

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Gonadotrophin-releasing hormone antagonists for assisted conception.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

The role of GnRH antagonists in assisted reproduction.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Gonadotropin-releasing hormone antagonist: new tools vs. old habits

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

The role of LHRH agonists and antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Embryo score to predict implantation after in-vitro fertilization: based on 957 single embryo transfers

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

The place of gonadotrophin-releasing hormone antagonists in reproductive medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Gonadotropin-releasing-hormone-receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Safety aspects of gonadotrophin-releasing hormone antagonists in ovarian stimulation procedures: ovarian hyperstimulation syndrome and health of children born.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Use of gonadotrophin releasing hormone (GnRH) antagonist (cetrotide) during ovarian stimulation for in-vitro fertilization treatment: multiple doses and single dose

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

GnRH antagonist in single-dose applications

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

The use of GnRH antagonists in ovarian stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

The LHRH antagonist cetrorelix: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961749-X

7 January 2021

Gonadotrophin-releasing hormone antagonists: will they replace the agonists?

9

1 reference

https://api.crossref.org/works/10.1016/S1472-6483(10)61749-X

23 March 2024

Identifiers

1 reference

4 December 2017

1 reference